IP Library Granted Patent US 7,285,640
Granted Patent B2
US 7,285,640 · App. 10/320,231 · Granted Oct 23, 2007

Antibody to stem cell factor

Assignee: Bayer Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,285,640
App. No.
10/320,231
Granted
Oct 23, 2007
Kind
B2
Abstract

The present invention provides human antibodies specific for stem cell factor that contain at least one CDR derived from a combinatorial antibody library. The invention also provides pharmaceutical compositions comprising the antibodies and methods of treating asthma. The invention further provides methods of detecting stem cell factor using the antibodies.

Claims (10)

1. A purified human antibody which binds to stem cell factor protein, said antibody comprising

a light chain variable region having the human Vκ1 consensus framework amino acid sequence, wherein light chain CDR 1 has the amino acid sequence of SEQ ID NO:59, light chain CDR 2 has the amino acid sequence of SEQ ID NO:69, and light chain CDR 3 has the amino acid sequence of SEQ ID NO:20; and

a heavy chain variable region having the human VH3 consensus framework amino acid sequence, wherein heavy chain CDR 1 has the amino acid sequence of residues 23-32 of SEQ ID NO:79, heavy chain CDR 2 has the amino acid sequence of residues 47-63 SEQ ID NO:79, and heavy chain CDR 3 has the amino acid sequence of SEQ ID NO:14,

said antibody being optionally bound to a cytotoxic molecule or detectable label.

2. The antibody of claim 1 wherein said antibody comprises heavy chain variable and constant regions having the amino acid sequence of SEQ ID NO: 77, and light chain variable and constant regions having the amino acid sequence of SEQ ID NO: 79.

3. The antibody of claim 1 wherein said antibody is a full-length antibody.

4. The antibody of claim 1 wherein said antibody is an IgG.

5. The antibody of claim 1 wherein said antibody is an antibody fragment.

6. A preparation comprising the antibody of claim 1 .

7. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

Assignments (4)
SECURITY AGREEMENT Recorded Mar 16, 2011
From: AEROVANCE INC.
To: OXFORD FINANCE CORPORATION; COMERICA BANK; SILICON VALLEY BANK
Reel/Frame 025967/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2007
From: BAYER PHARMACEUTICALS CORPORATION
To: AEROVANCE, INC.
Reel/Frame 019731/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2003
From: BAYER CORPORATION
To: BAYER PHARMACEUTICALS CORPORATION
Reel/Frame 014131/0509 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2003
From: TAKEUCHI, TOSHIHIKO; TOMKINSON, ADRIAN; NEBEN, STEVEN
To: BAYER CORPORATION
Reel/Frame 013389/0981 →
Continuity (2)
Provisional Application 6034217400 · Dec 17, 2001
Related Publication 20030194405A1 · Oct 16, 2003